Healthcare systems are strained to the breaking point as our population ages. Farmland is diminishing as the population swells. Climate change is reducing crop yields as more people go hungry every day. Today, and in the decades to come, new solutions must be discovered to provide quality health and food for at least ten billion people.
We feel it is our responsibility to set new benchmarks
Leaps by Bayer is spearheading a movement to make paradigm-shifting advances in the life sciences – targeting the breakthroughs that could fundamentally change the world for the better. Much of what we are aiming to achieve is not yet possible. Setbacks and failures are to be expected in dealing with such ambitious targets.
But with a 150-year history in the life sciences and capabilities across healthcare and agriculture, Bayer is able to see the bigger picture. We feel it is our responsibility to set new benchmarks; to find the courage to begin where others resist; and to drive breakthrough innovation. And we will not do it alone: we will collaborate with the world’s smartest minds in biotech.
Our TeamMultidisciplinary experts
working together for a shared purpose
Head of Leaps by Bayer
Head of Venture Investment
"We’re aware that the challenges we face are huge, as is the level of risk. We can’t even predict all the obstacles we will face along the way. But we have to be brave and leap into the unknown."
"When the goal is important enough, risking failure with a leap of faith is worth it – even if it doesn’t turn out to be successful."
HR Business Partner Innovation
"No single company or person will solve the huge challenges facing our planet. Scientists have to come together, to work together, and to try to achieve the breakthroughs we need."
Equity Portfolio Manager
"There’s no time to carry on as normal. To play it safe. And definitely no time to only target ROI. We also want to be measured by how many lives we save and improve. Our goal is real, lasting change - not profit only."
Our joint ventures Collaborating with the world’s smartest minds in biotech
The joint venture Casebia represents the first realization of a targeted investment (for five years or longer) in order to tackle the huge challenges Leaps by Bayer has defined. The objective of Casebia is to research curative treatments for several rare human diseases in Hematology/Autoimmune by utilizing CRISPR/Cas-based DNA editing.Learn more
With the creation of the joint venture BlueRock Therapeutics (for four years or longer), the focus lies on research around pluripotent stem cell technologies with the defined objective to create breakthrough innovations to cure Parkinson’s and chronic heart failure.Learn more